Enovis Overview
- Year Founded
-
1995

- Status
-
Public
- Employees
-
7,367

- Stock Symbol
-
ENOV

- Investments
-
39
- Share Price
-
$30.54
- (As of Wednesday Closing)
Enovis General Information
Description
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Contact Information
Website
www.enovis.comCorporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Corporate Office
- 2711 Centerville Road
- Suite 400
- Wilmington, DE 19808
- United States
Enovis Stock Performance
As of 16-Jul-2025, Enovis’s stock price is $30.54. Its current market cap is $1.74B with 57.1M shares.
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$30.54 | $30.90 | $28.83 - $49.83 | $1.74B | 57.1M | 1.31M | -$13.95 |
Enovis Financials Summary
As of 31-Mar-2025, Enovis has a trailing 12-month revenue of $2.15B.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 3,534,774 | 3,833,709 | 3,493,431 | 3,169,473 |
Revenue | 2,150,191 | 2,107,623 | 1,707,197 | 1,563,101 |
EBITDA | (471,909) | (481,028) | 169,730 | 241,693 |
Net Income | (809,462) | (825,494) | (33,261) | (13,292) |
Total Assets | 4,875,034 | 4,718,777 | 4,509,334 | 4,273,248 |
Total Debt | 1,458,868 | 1,404,301 | 536,416 | 334,819 |
Enovis Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Enovis Comparisons
Industry
Financing
Details
Enovis Competitors (1)
One of Enovis’s competitors is Zimmer Biomet Holdings, a Corporation company based in Warsaw, IN.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Zimmer Biomet Holdings | Corporation | Warsaw, IN |
Enovis Patents
Enovis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-D1084067-S1 | Torch handle | Active | 15-Feb-2023 | ||
US-20240130030-A1 | Methods for mixing fluids for a plasma cutting torch | Pending | 17-Oct-2022 | ||
US-D1067289-S1 | Welding component | Active | 14-Oct-2022 | ||
US-20240123538-A1 | Pistol grip for a processing torch | Pending | 12-Oct-2022 | ||
US-20240109145-A1 | Wire feeder to torch communication | Pending | 30-Sep-2022 | B23K9/0953 |
Enovis Signals
Enovis Investments & Acquisitions (39)
Enovis’s most recent deal was a Merger/Acquisition with Limacorporate for . The deal was made on 03-Jan-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Limacorporate | 03-Jan-2024 | Merger/Acquisition | Therapeutic Devices | ||
Precision AI Australia | 05-Oct-2023 | Merger/Acquisition | Therapeutic Devices | ||
SEAL External Fixation | 20-Jul-2023 | Merger/Acquisition | Therapeutic Devices | ||
Novastep | 28-Jun-2023 | Merger/Acquisition | Other Devices and Supplies | ||
Insight Medical Systems | 05-Jul-2022 | Merger/Acquisition | Surgical Devices |
Enovis ESG
Risk Overview
Risk Rating
Updated September, 17, 2024
31.09 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile

Healthcare
Industry
of 562
Rank
Percentile

Medical Devices
Subindustry
of 194
Rank
Percentile

Enovis Exits (1)
Enovis’s most recent exit was on 09-Jul-2013 from Clarus Fluid Intelligence. The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Clarus Fluid Intelligence | 09-Jul-2013 | Completed |
|
Enovis Affiliates
Subsidiaries (14)
Name | Industry | Location | Year Founded |
---|---|---|---|
Precision AI Australia | Fortitude Valley, Australia | 2019 | |
Insight Medical Systems | Austin, TX | 2016 | |
360 Med Care | Frenchs Forest, Australia | 2015 | |
Novastep | Englewood Cliffs, NJ | 2015 | |
Fairmount Automation | West Conshohocken, PA | 1996 |
Enovis FAQs
-
When was Enovis founded?
Enovis was founded in 1995.
-
Where is Enovis headquartered?
Enovis is headquartered in Wilmington, DE.
-
What is the size of Enovis?
Enovis has 7,367 total employees.
-
What industry is Enovis in?
Enovis’s primary industry is Therapeutic Devices.
-
Is Enovis a private or public company?
Enovis is a Public company.
-
What is Enovis’s stock symbol?
The ticker symbol for Enovis is ENOV.
-
What is the current stock price of Enovis?
As of 16-Jul-2025 the stock price of Enovis is $30.54.
-
What is the current market cap of Enovis?
The current market capitalization of Enovis is $1.74B.
-
What is Enovis’s current revenue?
The trailing twelve month revenue for Enovis is $2.15B.
-
Who are Enovis’s competitors?
Zimmer Biomet Holdings is a competitor of Enovis.
-
What is Enovis’s annual earnings per share (EPS)?
Enovis’s EPS for 12 months was -$13.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »